Adipo Therapeutic
Thomas Hardy currently serves as the Chief Medical Officer at Adipo Therapeutics since May 2025. Prior to this role, Thomas held the position of Vice President for Drug Safety and Pharmacovigilance at Immunovant from October 2021 to May 2025. Thomas's extensive experience in the medical field also includes over 18 years at Eli Lilly and Company, where positions included Senior Medical Director and Senior Medical Advisor. Academic credentials include an MD and PhD in Medicine and Biochemistry from Indiana University School of Medicine, complemented by studies at the University of California, Santa Cruz.
This person is not in any teams
This person is not in any offices
Adipo Therapeutic
1 followers
Adipo Therapeutic is a biotechnology company that develops polymer-based nanotherapeutics. Its nanotherapeutics utilizes adipocyte browning technique to convert energy-storing bad fat cells into energy-burning good fat cells to transform the treatment of obesity and type 2 diabetes, enabling patients to lose bodyweight naturally and restoringmetabolic balance for millions of people living with diabetes.